लोड हो रहा है...
Targeting neoplastic B cells and harnessing microenvironment: the “double face” of ibrutinib and idelalisib
Tyrosine kinase inhibitors (TKIs) targeting signaling molecules downstream B cell receptor (BCR) are powerfully spreading in the therapeutic landscape of B cell lymphoproliferative disease, due to a manageable toxicity profile and encouraging clinical effectiveness. In particular, ibrutinib, previou...
में बचाया:
| में प्रकाशित: | J Hematol Oncol |
|---|---|
| मुख्य लेखकों: | , , , , , |
| स्वरूप: | Artigo |
| भाषा: | Inglês |
| प्रकाशित: |
BioMed Central
2015
|
| विषय: | |
| ऑनलाइन पहुंच: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4459446/ https://ncbi.nlm.nih.gov/pubmed/26022368 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-015-0157-x |
| टैग : |
टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!
|